Epigenetic Drug Discovery:Targeting DNA Methyltransferases

Journal of Biomolecular Screening

Volumn 17, Issue 1, 2012, Pages 2-17

  Foulks, Jason M ^a   Parnell, K Mark ^a   Nix, Rebecca N ^a   Chau, Suzanna ^a   Swierczek, Krzysztof ^a   Saunders, Michael ^a   Wright, Kevin ^a   Hendrickson, Thomas F ^a   ho, Koc Kan ^a   Mccullar, Michael V ^a   Kanner, Steven B ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

career satisfaction scale; career success; latent mean differences; occupational and career context; occupational measurement invariance

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CP 4200; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; ENZYME INHIBITOR;

DNA METHYLATION; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DRUG DISCOVERY; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 84862681781     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057111421212     Document Type: Article

References (182)

1. Kornberg R. D. Chromatin Structure: A Repeating Unit of Histones and DNA. Science 1974, 184, 868–871.
2. Klug A. Rhodes D. Smith J. Finch J. T. Thomas J. O. A Low Resolution Structure for the Histone Core of the Nucleosome. Nature 1980, 287, 509–516.
3. Arents G. Burlingame R. W. Wang B. C. Love W. E. Moudrianakis E. N. The Nucleosomal Core Histone Octamer at 3.1 A Resolution: A Tripartite Protein Assembly and a Left-Handed Superhelix. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 10148–10152.
4. Luger K. Mader A. W. Richmond R. K. Sargent D. F. Richmond T. J. Crystal Structure of the Nucleosome Core Particle at 2.8 A Resolution. Nature 1997, 389, 251–260.
5. Herman J. G. Baylin S. B. Gene Silencing in Cancer in Association with Promoter Hypermethylation. N. Engl. J. Med. 2003, 349, 2042–254.
6. Jones P. A. Laird P. W. Cancer Epigenetics Comes of Age. Nat. Genet. 1999, 21, 163–167.
7. Kirmizis A. Bartley S. M. Kuzmichev A. Margueron R. Reinberg D. Green R. Farnham P. J. Silencing of Human Polycomb Target Genes Is Associated with Methylation of Histone H3 Lys 27. Genes Dev. 2004, 18, 1592–1605.
8. Laird P. W. Cancer Epigenetics. Hum. Mol. Genet. 2005, 14(Spec No 1), R65–R76.
9. Bird A. Perceptions of Epigenetics. Nature 2007, 447, 396–398.
10. Smith E. Shilatifard A. The A, B, Gs of Silencing. Genes Dev. 2007, 21, 1141–1144.
11. Gibney E. R. Nolan C. M. Epigenetics and Gene Expression. Heredity 2010, 105, 4–13.
12. Szyf M. A Dynamic Methylome: Implications of Non-CG Methylation/Demethylation. Cell Cycle 2010, 9, 3846–3847.
13. Upadhyay A. K. Cheng X. Dynamics of Histone Lysine Methylation: Structures of Methyl Writers and Erasers. Prog. Drug Res. 2011, 67, 107–124.
14. Taberlay P. C. Jones P. A. DNA Methylation and Cancer. Prog. Drug Res. 2011, 67, 1–23.
15. Miranda T. B. Jones P. A. DNA Methylation: The Nuts and Bolts of Repression. J. Cell Physiol. 2007, 213, 384–390.
16. Baylin S. B. Ohm J. E. Epigenetic Gene Silencing in Cancer: A Mechanism for Early Oncogenic Pathway Addiction? Nat. Rev. Cancer 2006, 6, 107–116.
17. Pedrali-Noy G. Weissbach A. Mammalian DNA Methyltransferases Prefer Poly(dI-dC) as Substrate. J. Biol. Chem. 1986, 261, 7600–7602.
18. Kim GD. Ni J. Kelesoglu N. Roberts R. J. Pradhan S. Co-operation and Communication between the Human Maintenance and De Novo DNA (cytosine-5) Methyltransferases. EMBO J. 2002, 21, 4183–4195.
19. Ross J. P. Suetake I. Tajima S. Molloy P. L. Recombinant Mammalian DNA Methyltransferase Activity on Model Transcriptional Gene Silencing Short RNA-DNA Heteroduplex Substrates. Biochem. J. 2010, 432, 323–332.
20. Chuang L. S. Ian H. I. Koh T. W. Ng H. H. Xu G. Li B. F. Human DNA-(Cytosine-5) Methyltransferase-PCNA Complex as a Target for p21WAF1. Science 1997, 277, 1996–2000.
21. Bostick M. Kim J. K. Esteve P. O. Clark A. Pradhan S. Jacobsen S. E. UHRF1 Plays a Role in Maintaining DNA Methylation in Mammalian Cells. Science 2007, 317, 1760–1764.
22. Spada F. Haemmer A. Kuch D. Rothbauer U. Schermelleh L. Kremmer E. Carell T. Langst G. Leonhardt H. DNMT1 but Not Its Interaction with the Replication Machinery Is Required for Maintenance of DNA Methylation in Human Cells. J. Cell Biol. 2007, 176, 565–571.
23. Li E. Bestor T. H. Jaenisch R. Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality. Cell 1992, 69, 915–926.
24. Muto M. Kanari Y. Kubo E. Takabe T. Kurihara T. Fujimori A. Tatsumi K. Targeted Disruption of Np95 Gene Renders Murine Embryonic Stem Cells Hypersensitive to DNA Damaging Agents and DNA Replication Blocks. J. Biol. Chem. 2002, 277, 34549–34555.
25. Lei H. Oh S. P. Okano M. Juttermann R. Goss K. A. Jaenisch R. Li E. De Novo DNA Cytosine Methyltransferase Activities in Mouse Embryonic Stem Cells. Development 1996, 122, 3195–3205.
26. Jackson-Grusby L. Beard C. Possemato R. Tudor M. Fambrough D. Csankovszki G. Dausman J. Lee P. Wilson C. Lander E. Loss of Genomic Methylation Causes p53-Dependent Apoptosis and Epigenetic Deregulation. Nat. Genet. 2001, 27, 31–39.
27. Sharif J. Muto M. Takebayashi S. Suetake I. Iwamatsu A. Endo T. A. Shinga J. Mizutani-Koseki Y. Toyoda T. Okamura K. The SRA Protein Np95 Mediates Epigenetic Inheritance by Recruiting Dnmt1 to Methylated DNA. Nature 2007, 450, 908–912.
28. Egger G. Jeong S. Escobar S. G. Cortez C. C. Li T. W. Saito Y. Yoo C. B. Jones P. A. Liang G. Identification of DNMT1 (DNA Methyltransferase 1) Hypomorphs in Somatic Knockouts Suggests an Essential Role for DNMT1 in Cell Survival. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 14080–14085.
29. Chen T. Hevi S. Gay F. Tsujimoto N. He T. Zhang B. Ueda Y. Li E. Complete Inactivation of DNMT1 Leads to Mitotic Catastrophe in Human Cancer Cells. Nat. Genet. 2007, 39, 391–396.
30. Goll M. G. Kirpekar F. Maggert K. A. Yoder J. A. Hsieh C. L. Zhang X. Golic K. G. Jacobsen S. E. Bestor T. H. Methylation of tRNAAsp by the DNA Methyltransferase Homolog Dnmt2. Science 2006, 311, 395–398.
31. Schaefer M. Lyko F. Solving the Dnmt2 Enigma. Chromosoma 2010, 119, 35–40.
32. Okano M. Bell D. W. Haber D. A. Li E. DNA methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development. Cell 1999, 99, 247–257.
33. Gowher H. Jeltsch A. Molecular Enzymology of the Catalytic Domains of the Dnmt3a and Dnmt3b DNA Methyltransferases. J. Biol. Chem. 2002, 277, 20409–20414.
34. Goll M. G. Bestor T. H. Eukaryotic Cytosine Methyltransferases. Annu. Rev. Biochem. 2005, 74, 481–514.
35. Rhee I. Bachman K. E. Park B. H. Jair K. W. Yen R. W. Schuebel K. E. Cui H. Feinberg A. P. Lengauer C. Kinzler K. W. DNMT1 and DNMT3b Cooperate to Silence Genes in Human Cancer Cells. Nature 2002, 416, 526–552.
36. Liang G. Chan M. F. Tomigahara Y. Tsai Y. C. Gonzales F. A. Li E. Laird P. W. Jones P. A. Cooperativity between DNA Methyltransferases in the Maintenance Methylation of Repetitive Elements. Mol. Cell Biol. 2002, 22, 480–491.
37. Chen T. Ueda Y. Dodge J. E. Wang Z. Li E. Establishment and Maintenance of Genomic Methylation Patterns in Mouse Embryonic Stem Cells by Dnmt3a and Dnmt3b. Mol. Cell Biol. 2003, 23, 5594–5605.
38. Kaneda M. Okano M. Hata K. Sado T. Tsujimoto N. Li E. Sasaki H. Essential Role for De Novo DNA Methyltransferase Dnmt3a in Paternal and Maternal Imprinting. Nature 2004, 429, 900–903.
39. Bourc'his D. Xu G. L. Lin C. S. Bollman B. Bestor T. H. Dnmt3L and the Establishment of Maternal Genomic Imprints. Science 2001, 294, 2536–2539.
40. Bourc'his D. Bestor T. H. Meiotic Catastrophe and Retrotransposon Reactivation in Male Germ Cells Lacking Dnmt3L. Nature 2004, 431, 96–99.
41. Hata K. Okano M. Lei H. Li E. Dnmt3L Cooperates with the Dnmt3 Family of De Novo DNA Methyltransferases to Establish Maternal Imprints in Mice. Development 2002, 129, 1983–1993.
42. Gowher H. Liebert K. Hermann A. Xu G. Jeltsch A. Mechanism of Stimulation of Catalytic Activity of Dnmt3A and Dnmt3B DNA-(Cytosine-C5)-Methyltransferases by Dnmt3L. J. Biol. Chem. 2005, 280, 13341–13348.
43. Jia D. Jurkowska R. Z. Zhang X. Jeltsch A. Cheng X. Structure of Dnmt3a Bound to Dnmt3L Suggests a Model for De Novo DNA Methylation. Nature 2007, 449, 248–251.
44. Klein C. J. Botuyan M. V. Wu Y. Ward C. J. Nicholson G. A. Hammans S. Hojo K. Yamanishi H. Karpf A. R. Wallace D. C. Mutations in DNMT1 Cause Hereditary Sensory Neuropathy with Dementia and Hearing Loss. Nat Genet 2011, 43, 595–600.
45. Margot J. B. Aguirre-Arteta A. M. Di Giacco B. V. Pradhan S. Roberts R. J. Cardoso M. C. Leonhardt H. Structure and Function of the Mouse DNA Methyltransferase Gene: Dnmt1 Shows a Tripartite Structure. J. Mol. Biol. 2000, 297, 293–300.
46. Xu G. L. Bestor T. H. Bourc'his D. Hsieh C. L. Tommerup N. Bugge M. Hulten M. Qu X. Russo J. J. Viegas-Pequignot E. Chromosome Instability and Immunodeficiency Syndrome Caused by Mutations in a DNA Methyltransferase Gene. Nature 1999, 402, 187–191.
47. Ehrlich M. Sanchez C. Shao C. Nishiyama R. Kehrl J. Kuick R. Kubota T. Hanash S. M. ICF, an Immunodeficiency Syndrome: DNA Methyltransferase 3B Involvement, Chromosome Anomalies, and Gene Dysregulation. Autoimmunity 2008, 41, 253–271.
48. Narayan A. Tuck-Muller C. Weissbecker K. Smeets D. Ehrlich M. Hypersensitivity to Radiation-Induced Non-Apoptotic and Apoptotic Death in Cell Lines from Patients with the ICF Chromosome Instability Syndrome. Mutat. Res. 2000, 456, 1–15.
49. Walter M. J. Ding L. Shen D. Shao J. Grillot M. McLellan M. Fulton R. Schmidt H. Kalicki-Veizer J. O’Laughlin M. Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes. Leukemia 2011, 25, 1153–1158.
50. Ley T. J. Ding L. Walter M. J. McLellan M. D. Lamprecht T. Larson D. E. Kandoth C. Payton J. E. Baty J. Welch J. DNMT3A Mutations in Acute Myeloid Leukemia. N. Engl. J. Med. 2010, 363, 2424–2433.
51. Yan X. J. Xu J. Gu Z. H. Pan C. M. Lu G. Shen Y. Shi J. Y. Zhu Y. M. Tang L. Exome Sequencing Identifies Somatic Mutations of DNA Methyltransferase Gene DNMT3A in Acute Monocytic Leukemia. Nat. Genet. 2011, 43, 309–315.
52. Eklund E. A. The Role of HOX Genes in Malignant Myeloid Disease. Curr. Opin. Hematol. 2007, 14, 85–89.
53. Shah N. Sukumar S. The Hox Genes and Their Roles in Oncogenesis. Nat. Rev. Cancer 2010, 10, 361–371.
54. Feinberg A. P. Vogelstein B. Hypomethylation Distinguishes Genes of Some Human Cancers from Their Normal Counterparts. Nature 1983, 301, 89–92.
55. Riggs A. D. Jones P. A. 5-Methylcytosine, Gene Regulation, and Cancer. Adv. Cancer Res. 1983, 40, 1–30.
56. Arnold C. N. Goel A. Niedzwiecki D. Dowell J. M. Wasserman L. Compton C. Mayer R. J. Bertagnolli M. M. Boland C. R. APC Promoter Hypermethylation Contributes to the Loss of APC Expression in Colorectal Cancers with Allelic Loss on 5q. Cancer Biol. Ther. 2004, 3, 960–964.
57. Chen J. Rocken C. Lofton-Day C. Schulz H. U. Muller O. Kutzner N. Malfertheiner P. Ebert M. P. Molecular Analysis of APC Promoter Methylation and Protein Expression in Colorectal Cancer Metastasis. Carcinogenesis 2005, 26, 37–43.
58. Virmani A. K. Rathi A. Sathyanarayana U. G. Padar A. Huang C. X. Cunnigham H. T. Farinas A. J. Milchgrub S. Euhus D. M. Gilcrease M. Aberrant Methylation of the Adenomatous Polyposis Coli (APC) Gene Promoter 1A in Breast and Lung Carcinomas. Clin. Cancer Res. 2001, 7, 1998–2004.
59. Esteller M. Corn P. G. Baylin S. B. Herman J. G. A Gene Hypermethylation Profile of Human Cancer. Cancer Res. 2001, 61, 3225–3229.
60. Dobrovic A. Simpfendorfer D. Methylation of the BRCA1 Gene in Sporadic Breast Cancer. Cancer Res. 1997, 57, 3347–3350.
61. Esteller M. Silva J. M. Dominguez G. Bonilla F. Matias-Guiu X. Lerma E. Bussaglia E. Prat J. Harkes I. C. Repasky E. A. Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors. J. Natl. Cancer Inst. 2000, 92, 564–569.
62. Turner N. C. Reis-Filho J. S. Russell A. M. Springall R. J. Ryder K. Steele D. Savage K. Gillett C. E. Schmitt F. C. Ashworth A. BRCA1 Dysfunction in Sporadic Basal-Like Breast Cancer. Oncogene 2007, 26, 2126–2132.
63. Herman J. G. Merlo A. Mao L. Lapidus R. G. Issa J. P. Davidson N. E. Sidransky D. Baylin S. B. Inactivation of the CDKN2/p16/MTS1 Gene Is Frequently Associated with Aberrant DNA Methylation in All Common Human Cancers. Cancer Res. 1995, 55, 4525–4530.
64. Esteller M. Fraga M. F. Guo M. Garcia-Foncillas J. Hedenfalk I. Godwin A. K. Trojan J. Vaurs-Barriere C. Bignon Y. J. Ramus S. DNA Methylation Patterns in Hereditary Human Cancers Mimic Sporadic Tumorigenesis. Hum. Mol. Genet. 2001, 10, 3001–3007.
65. Toyooka S. Toyooka K. O. Maruyama R. Virmani A. K. Girard L. Miyajima K. Harada K. Ariyoshi Y. Takahashi T. Sugio K. DNA Methylation Profiles of Lung Tumors. Mol. Cancer Ther. 2001, 1, 61–67.
66. Rosas S. L. Koch W. da Costa Carvalho M. G. Wu L. Califano J. Westra W. Jen J. Sidransky D. Promoter Hypermethylation Patterns of p16, O6-Methylguanine-DNA-Methyltransferase, and Death-Associated Protein Kinase in Tumors and Saliva of Head and Neck Cancer Patients. Cancer Res. 2001, 61, 939–942.
67. Sanchez-Cespedes M. Esteller M. Wu L. Nawroz-Danish H. Yoo G. H. Koch W. M. Jen J. Herman J. G. Sidransky D. Gene Promoter Hypermethylation in Tumors and Serum of Head and Neck Cancer Patients. Cancer Res. 2000, 60, 892–895.
68. Herman J. G. Jen J. Merlo A. Baylin S. B. Hypermethylation-Associated Inactivation Indicates a Tumor Suppressor Role for p15INK4B. Cancer Res. 1996, 56, 722–727.
69. Batova A. Diccianni M. B. Yu J. C. Nobori T. Link M. P. Pullen J. Yu A. L. Frequent and Selective Methylation of p15 and Deletion of Both p15 and p16 in T-Cell Acute Lymphoblastic Leukemia. Cancer Res. 1997, 57, 832–836.
70. Graff J. R. Herman J. G. Lapidus R. G. Chopra H. Xu R. Jarrard D. F. Isaacs W. B. Pitha P. M. Davidson N. E. Baylin S. B. E-Cadherin Expression Is Silenced by DNA hypermethylation in Human Breast and Prostate Carcinomas. Cancer Res. 1995, 55, 5195–5199.
71. Graff J. R. Greenberg V. E. Herman J. G. Westra W. H. Boghaert E. R. Ain K. B. Saji M. Zeiger M. A. Zimmer S. G. Baylin S. B. Distinct Patterns of E-Cadherin CpG Island Methylation in Papillary, Follicular, Hurthle's Cell, and Poorly Differentiated Human Thyroid Carcinoma. Cancer Res. 1998, 58, 2063–2066.
72. Lapidus R. G. Ferguson A. T. Ottaviano Y. L. Parl F. F. Smith H. S. Weitzman S. A. Baylin S. B. Issa J. P. Davidson N. E. Methylation of Estrogen and Progesterone Receptor Gene 5′ CpG Islands Correlates with Lack of Estrogen and Progesterone Receptor Gene Expression in Breast Tumors. Clin. Cancer Res. 1996, 2, 805–810.
73. Ottaviano Y. L. Issa J. P. Parl F. F. Smith H. S. Baylin S. B. Davidson N. E. Methylation of the Estrogen Receptor Gene CpG Island Marks Loss of Estrogen Receptor Expression in Human Breast Cancer Cells. Cancer Res. 1994, 54, 2552–2555.
74. Issa J. P. Baylin S. B. Belinsky S. A. Methylation of the Estrogen Receptor CpG Island in Lung Tumors Is Related to the Specific Type of Carcinogen Exposure. Cancer Res. 1996, 56, 3655–3658.
75. Issa J. P. Zehnbauer B. A. Civin C. I. Collector M. I. Sharkis S. J. Davidson N. E. Kaufmann S. H. Baylin S. B. The Estrogen Receptor CpG Island Is Methylated in Most Hematopoietic Neoplasms. Cancer Res. 1996, 56, 973–977.
76. Yan L. Yang X. Davidson N. E. Role of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer. J. Mammary Gland Biol. Neoplasia 2001, 6, 183–92.
77. Li L. C. Chui R. Nakajima K. Oh B. R. Au H. C. Dahiya R. Frequent Methylation of Estrogen Receptor in Prostate Cancer: Correlation with Tumor Progression. Cancer Res. 2000, 60, 702–706.
78. Samowitz W. S. Albertsen H. Herrick J. Levin T. R. Sweeney C. Murtaugh M. A. Wolff R. K. Slattery M. L. Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon Cancer. Gastroenterology 2005, 129, 837–845.
79. Watanabe Y. Ueda H. Etoh T. Koike E. Fujinami N. Mitsuhashi A. Hoshiai H. A Change in Promoter Methylation of hMLH1 Is a Cause of Acquired Resistance to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer. Anticancer Res. 2007, 27, 1449–1452.
80. Herman J. G. Umar A. Polyak K. Graff J. R. Ahuja N. Issa J. P. Markowitz S. Willson J. K. Hamilton S. R. Kinzler K. W. Incidence and Functional Consequences of hMLH1 Promoter Hypermethylation in Colorectal Carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 6870–6875.
81. Kane M. F. Loda M. Gaida G. M. Lipman J. Mishra R. Goldman H. Jessup J. M. Kolodner R. Methylation of the hMLH1 Promoter Correlates with Lack of Expression of hMLH1 in Sporadic Colon Tumors and Mismatch Repair-Defective Human Tumor Cell Lines. Cancer Res. 1997, 57, 808–811.
82. Esteller M. Levine R. Baylin S. B. Ellenson L. H. Herman J. G. MLH1 Promoter Hypermethylation Is Associated with the Microsatellite Instability Phenotype in Sporadic Endometrial Carcinomas. Oncogene 1998, 17, 2413–2417.
83. Leung S. Y. Yuen S. T. Chung L. P. Chu K. M. Chan A. S. Ho J. C. hMLH1 Promoter Methylation and Lack of hMLH1 Expression in Sporadic Gastric Carcinomas with High-Frequency Microsatellite Instability. Cancer Res. 1999, 59, 159–164.
84. Agathanggelou A. Honorio S. Macartney D. P. Martinez A. Dallol A. Rader J. Fullwood P. Chauhan A. Walker R. Shaw J. A. Methylation Associated Inactivation of RASSF1A from Region 3p21.3 in Lung, Breast and Ovarian Tumours. Oncogene 2001, 20, 1509–1518.
85. Choi Y. L. Kang S. Y. Shin Y. K. Choi J. S. Kim S. H. Lee S. J. Bae D. S. Ahn G. Aberrant Hypermethylation of RASSF1A Promoter in Ovarian Borderline Tumors and Carcinomas. Virchows Arch 2006, 448, 331–336.
86. Greger V. Debus N. Lohmann D. Hopping W. Passarge E. Horsthemke B. Frequency and Parental Origin of Hypermethylated RB1 Alleles in Retinoblastoma. Hum. Genet. 1994, 94, 491–496.
87. Stirzaker C. Millar D. S. Paul C. L. Warnecke P. M. Harrison J. Vincent P. C. Frommer M. Clark S. J. Extensive DNA Methylation Spanning the Rb Promoter in Retinoblastoma Tumors. Cancer Res. 1997, 57, 2229–2237.
88. Gonzalez-Gomez P. Bello M. J. Alonso M. E. Arjona D. Lomas J. de Campos J. M. Isla A. Rey J. A. CpG Island Methylation Status and Mutation Analysis of the RB1 Gene Essential Promoter Region and Protein-Binding Pocket Domain in Nervous System Tumours. Br. J. Cancer 2003, 88, 109–114.
89. Herman J. G. Latif F. Weng Y. Lerman M. I. Zbar B. Liu S. Samid D. Duan D. S. Gnarra J. R. Linehan W. M. Silencing of the VHL Tumor-Suppressor Gene by DNA Methylation in Renal Carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 9700–9704.
90. Clifford S. C. Prowse A. H. Affara N. A. Buys C. H. Maher E. R. Inactivation of the von Hippel-Lindau (VHL) Tumour Suppressor Gene and Allelic Losses at Chromosome Arm 3p in Primary Renal Cell Carcinoma: Evidence for a VHL-Independent Pathway in Clear Cell Renal Tumourigenesis. Genes Chromosomes Cancer 1998, 22, 200–209.
91. Kurkjian C. Kummar S. Murgo A. J. DNA Methylation: Its Role in Cancer Development and Therapy. Curr. Probl. Cancer 2008, 32, 187–235.
92. Eads C. A. Nickel A. E. Laird P. W. Complete Genetic Suppression of Polyp Formation and Reduction of CpG-Island Hypermethylation in Apc(Min/+) Dnmt1-Hypomorphic Mice. Cancer Res. 2002, 62, 1296–1299.
93. Lin H. Yamada Y. Nguyen S. Linhart H. Jackson-Grusby L. Meissner A. Meletis K. Lo G. Jaenisch R. Suppression of Intestinal Neoplasia by Deletion of Dnmt3b. Mol. Cell Biol. 2006, 26, 2976–2983.
94. Linhart H. G. Lin H. Yamada Y. Moran E. Steine E. J. Gokhale S. Lo G. Cantu E. Ehrich M. He T. Dnmt3b Promotes Tumorigenesis In Vivo by Gene-Specific De Novo Methylation and Transcriptional Silencing. Genes Dev. 2007, 21, 3110–3122.
95. Fabbri M. Calin G. A. Epigenetics and miRNAs in Human Cancer. Adv. Genet. 2010, 70, 87–99.
96. Roman-Gomez J. Agirre X. Jimenez-Velasco A. Arqueros V. Vilas-Zornoza A. Rodriguez-Otero P. Martin-Subero I. Garate L. Cordeu L. San Jose-Eneriz E. Epigenetic Regulation of microRNAs in Acute Lymphoblastic Leukemia. J. Clin. Oncol. 2009, 27, 1316–1322.
97. Agirre X. Vilas-Zornoza A. Jimenez-Velasco A. Martin-Subero J. I. Cordeu L. Garate L. San Jose-Eneriz E. Abizanda G. Rodriguez-Otero P. Fortes P. Epigenetic Silencing of the Tumor Suppressor microRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia. Cancer Res. 2009, 69, 4443–4453.
98. Miremadi A. Oestergaard M. Z. Pharoah P. D. Caldas C. Cancer Genetics of Epigenetic Genes. Hum. Mol. Genet. 2007, 16(Spec No 1), R28–R49.
99. Yi J. M. Tsai H. C. Glockner S. C. Lin S. Ohm J. E. Easwaran H. James C. D. Costello J. F. Riggins G. Eberhart C. G. Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors. Cancer Res. 2008, 68, 8094–8103.
100. Saito Y. Kanai Y. Sakamoto M. Saito H. Ishii H. Hirohashi S. Overexpression of a Splice Variant of DNA Methyltransferase 3b, DNMT3b4, Associated with DNA Hypomethylation on Pericentromeric Satellite Regions during Human Hepatocarcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 10060–10065.
101. Wang J. Walsh G. Liu D. D. Lee J. J. Mao L. Expression of Delta DNMT3B Variants and Its Association with Promoter Methylation of p16 and RASSF1A in Primary Non-Small Cell Lung Cancer. Cancer Res. 2006, 66, 8361–8366.
102. Wang L. Wang J. Sun S. Rodriguez M. Yue P. Jang S. J. Mao L. A Novel DNMT3B Subfamily, DeltaDNMT3B, Is the Predominant Form of DNMT3B in Non-Small Cell Lung Cancer. Int. J. Oncol. 2006, 29, 201–207.
103. Ostler K. R. Davis E. M. Payne S. L. Gosalia B. B. Exposito-Cespedes J. Le Beau M. M. Godley L. A. Cancer Cells Express Aberrant DNMT3B Transcripts Encoding Truncated Proteins. Oncogene 2007, 26, 5553–5563.
104. Eden A. Gaudet F. Waghmare A. Jaenisch R. Chromosomal Instability and Tumors Promoted by DNA Hypomethylation. Science 2003, 300, 455.
105. Gaudet F. Hodgson J. G. Eden A. Jackson-Grusby L. Dausman J. Gray J. W. Leonhardt H. Jaenisch R. Induction of Tumors in Mice by Genomic Hypomethylation. Science 2003, 300, 489–492.
106. Dodge J. E. Okano M. Dick F. Tsujimoto N. Chen T. Wang S. Ueda Y. Dyson N. Li E. Inactivation of Dnmt3b in Mouse Embryonic Fibroblasts Results in DNA Hypomethylation, Chromosomal Instability, and Spontaneous Immortalization. J. Biol. Chem. 2005, 280, 17986–17991.
107. Chen R. Z. Pettersson U. Beard C. Jackson-Grusby L. Jaenisch R. DNA Hypomethylation Leads to Elevated Mutation Rates. Nature 1998, 395, 89–93.
108. Brown K. D. Robertson K. D. DNMT1 Knockout Delivers a Strong Blow to Genome Stability and Cell Viability. Nat. Genet. 2007, 39, 289–290.
109. Haas P. S. Wijermans P. Verhoef G. Lubbert M. Treatment of Myelodysplastic Syndrome with a DNA Methyltransferase Inhibitor: Lack of Evidence for Induction of Chromosomal Instability. Leuk. Res. 2006, 30, 338–342.
110. Liang G. Gonzales F. A. Jones P. A. Orntoft T. F. Thykjaer T. Analysis of Gene Induction in Human Fibroblasts and Bladder Cancer Cells Exposed to the Methylation Inhibitor 5-aza-2′-deoxycytidine. Cancer Res. 2002, 62, 961–966.
111. Issa J. P. Kantarjian H. M. Targeting DNA Methylation. Clin. Cancer Res. 2009, 15, 3938–3946.
112. Yoo C. B. Jones P. A. Epigenetic Therapy of Cancer: Past, Present and Future. Nat. Rev. Drug Discov. 2006, 5, 37–50.
113. Jones P. A. Taylor S. M. Cellular Differentiation, Cytidine Analogs and DNA Methylation. Cell 1980, 20, 85–93.
114. Santi D. V. Norment A. Garrett C. E. Covalent Bond Formation between a DNA-Cytosine Methyltransferase and DNA Containing 5-Azacytosine. Proc. Natl. Acad. Sci. U. S. A. 1984, 81, 6993–6997.
115. Ghoshal K. Datta J. Majumder S. Bai S. Kutay H. Motiwala T. Jacob S. T. 5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal. Mol. Cell Biol. 2005, 25, 4727–4741.
116. Qin T. Youssef E. M. Jelinek J. Chen R. Yang A. S. Garcia-Manero G. Issa J. P. Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines. Clin. Cancer Res. 2007, 13, 4225–4232.
117. Hollenbach P. W. Nguyen A. N. Brady H. Williams M. Ning Y. Richard N. Krushel L. Aukerman S. L. Heise C. MacBeth K. J. A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines. PLoS One 2010, 5, e9001.
118. Stresemann C. Lyko F. Modes of Action of the DNA Methyltransferase Inhibitors Azacytidine and Decitabine. Int. J. Cancer 2008, 123, 8–13.
119. Velez-Garcia E. Vogler W. R. Bartolucci A. A. Arkun S. N. Twice Weekly 5-Azacytidine Infusion in Dissmeinated Metastatic Cancer: A Phase II Study. Cancer Treat. Rep. 1977, 61, 1675–1677.
120. Srinivasan U. Reaman G. H. Poplack D. G. Glaubiger D. L. LeVine A. S. Phase II Study of 5-Azacytidine in Sarcomas of Bone. Am. J. Clin. Oncol. 1982, 5, 411–415.
121. Momparler R. L. Rivard G. E. Gyger M. Clinical Trial on 5-Aza-2′-Deoxycytidine in Patients with Acute Leukemia. Pharmacol. Ther. 1985, 30, 277–286.
122. Silverman L. R. Demakos E. P. Peterson B. L. Kornblith A. B. Holland J. C. Odchimar-Reissig R. Stone R. M. Nelson D. Powell B. L. DeCastro C. M. Randomized Controlled Trial of Azacitidine in Patients with the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B. J. Clin. Oncol. 2002, 20, 2429–2440.
123. Kornblith A. B. Herndon J. E. II Silverman L. R. Demakos E. P. Odchimar-Reissig R. Holland J. F. Powell B. L. DeCastro C. Ellerton J. Larson R. A. Impact of Azacytidine on the Quality of Life of Patients with Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study. J. Clin. Oncol. 2002, 20, 2441–2452.
124. Silverman L. R. McKenzie D. R. Peterson B. L. Holland J. F. Backstrom J. T. Beach C. L. Larson R. A. Further Analysis of Trials with Azacitidine in Patients with Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 2006, 24, 3895–3903.
125. Fenaux P. Mufti G. J. Hellstrom-Lindberg E. Santini V. Finelli C. Giagounidis A. Schoch R. Gattermann N. Sanz G. List A. Efficacy of Azacitidine Compared with That of Conventional Care Regimens in the Treatment of Higher-Risk Myelodysplastic Syndromes: A Randomised, Open-Label, Phase III Study. Lancet Oncol. 2009, 10, 223–232.
126. Kantarjian H. Issa J. P. Rosenfeld C. S. Bennett J. M. Albitar M. DiPersio J. Klimek V. Slack J. de Castro C. Ravandi F. Decitabine Improves Patient Outcomes in Myelodysplastic Syndromes: Results of a Phase III Randomized Study. Cancer 2006, 106, 1794–1803.
127. Issa J. P. Garcia-Manero G. Giles F. J. Mannari R. Thomas D. Faderl S. Bayar E. Lyons J. Rosenfeld C. S. Cortes J. Phase 1 Study of Low-Dose Prolonged Exposure Schedules of the Hypomethylating Agent 5-Aza-2′-Deoxycytidine (Decitabine) in Hematopoietic Malignancies. Blood 2004, 103, 1635–1640.
128. Kantarjian H. Oki Y. Garcia-Manero G. Huang X. O’Brien S. Cortes J. Faderl S. Bueso-Ramos C. Ravandi F. Estrov Z. Results of a Randomized Study of 3 Schedules of Low-Dose Decitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Blood 2007, 109, 52–57.
129. Steensma D. P. Baer M. R. Slack J. L. Buckstein R. Godley L. A. Garcia-Manero G. Albitar M. Larsen J. S. Arora S. Cullen M. T. Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. J. Clin. Oncol. 2009, 27, 3842–3848.
130. Cashen A. F. Schiller G. J. O’Donnell M. R. DiPersio J. F. Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients with Acute Myeloid Leukemia. J. Clin. Oncol. 2010, 28, 556–561.
131. Shen L. Kantarjian H. Guo Y. Lin E. Shan J. Huang X. Berry D. Ahmed S. Zhu W. Pierce S. DNA Methylation Predicts Survival and Response to Therapy in Patients with Myelodysplastic Syndromes. J. Clin. Oncol. 2010, 28, 605–613.
132. Fang F. Balch C. Schilder J. Breen T. Zhang S. Shen C. Li L. Kulesavage C. Snyder A. J. Nephew K. P. A Phase 1 and Pharmacodynamic Study of Decitabine in Combination with Carboplatin in Patients with Recurrent, Platinum-Resistant, Epithelial Ovarian Cancer. Cancer 2010, 116, 4043–4053.
133. http://www.standup2cancer.org/node/4446
134. Byun H. M. Choi S. H. Laird P. W. Trinh B. Siddiqui M. A. Marquez V. E. Yang A. S. 2′-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-Azacytidine: A Novel Inhibitor of DNA Methyltransferase That Requires Activation by Human Carboxylesterase 1. Cancer Lett. 2008, 266, 238–248.
135. Yoo C. B. Jeong S. Egger G. Liang G. Phiasivongsa P. Tang C. Redkar S. Jones P. A. Delivery of 5-Aza-2′-Deoxycytidine to Cells Using Oligodeoxynucleotides. Cancer Res. 2007, 67, 6400–6408.
136. Chuang J. C. Warner S. L. Vollmer D. Vankayalapati H. Redkar S. Bearss D. J. Qiu X. Yoo C. B. Jones P. A. S110, a 5-Aza-2′-Deoxycytidine-Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In Vivo and Can Reduce Tumor Growth. Mol. Cancer Ther. 2010, 9, 1443–1450.
137. Lavelle D. Saunthararajah Y. Vaitkus K. Singh M. Banzon V. Phiasivongsva P. Redkar S. Kanekal S. Bearss D. Shi C. S110, a Novel Decitabine Dinucleotide, Increases Fetal Hemoglobin Levels in Baboons (P. anubis). J. Transl. Med. 2010, 8, 92.
138. Brueckner B. Rius M. Markelova M. R. Fichtner I. Hals P. A. Sandvold M. L. Lyko F: Delivery of 5-Azacytidine to Human Cancer Cells by Elaidic Acid Esterification Increases Therapeutic Drug Efficacy. Mol. Cancer Ther. 2010, 9, 1256–1264.
139. McGregor D. B. Brown A. G. Cattanach P. Shepherd W. Riach C. Daston D. S. Caspary W. J. TFT and 6TG Resistance of Mouse Lymphoma Cells to Analogs of Azacytidine. Carcinogenesis 1989, 10, 2003–2008.
140. Osterman D. G. DePillis G. D. Wu J. C. Matsuda A. Santi D. V. 5-Fluorocytosine in DNA Is a Mechanism-Based Inhibitor of HhaI Methylase. Biochemistry 1988, 27, 5204–5210.
141. Champion C. Guianvarc'h D. Senamaud-Beaufort C. Jurkowska R. Z. Jeltsch A. Ponger L. Arimondo P. B. Guieysse-Peugeot A. L. Mechanistic Insights on the Inhibition of c5 DNA Methyltransferases by Zebularine. PLoS One 2010, 5, e12388.
142. Newman E. M. Santi D. V. Metabolism and Mechanism of Action of 5-Fluorodeoxycytidine. Proc. Natl. Acad. Sci. U. S. A. 1982, 79, 6419–6423.
143. Flotho C. Claus R. Batz C. Schneider M. Sandrock I. Ihde S. Plass C. Niemeyer C. M. Lubbert M. The DNA Methyltransferase Inhibitors Azacitidine, Decitabine and Zebularine Exert Differential Effects on Cancer Gene Expression in Acute Myeloid Leukemia Cells. Leukemia 2009, 23, 1019–1028.
144. Amato R. J. Inhibition of DNA Methylation by Antisense Oligonucleotide MG98 as Cancer Therapy. Clin. Genitourin. Cancer 2007, 5, 422–426.
145. Winquist E. Knox J. Ayoub J. P. Wood L. Wainman N. Reid G. K. Pearce L. Shah A. Eisenhauer E. Phase II Trial of DNA Methyltransferase 1 Inhibition with the Antisense Oligonucleotide MG98 in Patients with Metastatic Renal Carcinoma: A National Cancer Institute of Canada Clinical Trials Group Investigational New Drug Study. Invest. New Drugs 2006, 24, 159–167.
146. Klisovic R. B. Blum W. Wei X. Liu S. Liu Z. Xie Z. Vukosavljevic T. Kefauver C. Huynh L. Pang J. Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia. Clin. Cancer Res. 2008, 14, 3889–3895.
147. Plummer R. Vidal L. Griffin M. Lesley M. de Bono J. Coulthard S. Sludden J. Siu L. L. Chen E. X. Oza A. M. Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2009, 15, 3177–3183.
148. Garzon R. Heaphy C. E. Havelange V. Fabbri M. Volinia S. Tsao T. Zanesi N. Kornblau S. M. Marcucci G. Calin G. A. MicroRNA 29b Functions in Acute Myeloid Leukemia. Blood 2009, 114, 5331–5341.
149. Qin T. Jelinek J. Si J. Shu J. Issa J. P. Mechanisms of Resistance to 5-Aza-2′-Deoxycytidine in Human Cancer Cell Lines. Blood 2009, 113, 659–667.
150. Cornacchia E. Golbus J. Maybaum J. Strahler J. Hanash S. Richardson B. Hydralazine and Procainamide Inhibit T Cell DNA Methylation and Induce Autoreactivity. J. Immunol. 1988, 140, 2197–2200.
151. Segura-Pacheco B. Trejo-Becerril C. Perez-Cardenas E. Taja-Chayeb L. Mariscal I. Chavez A. Acuna C. Salazar A. M. Lizano M. Duenas-Gonzalez A. Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy. Clin. Cancer Res. 2003, 9, 1596–1603.
152. Deng C. Lu Q. Zhang Z. Rao T. Attwood J. Yung R. Richardson B. Hydralazine May Induce Autoimmunity by Inhibiting Extracellular Signal-Regulated Kinase Pathway Signaling. Arthritis Rheum. 2003, 48, 746–756.
153. Chuang J. C. Yoo C. B. Kwan J. M. Li T. W. Liang G. Yang A. S. Jones P. A. Comparison of Biological Effects of Non-Nucleoside DNA Methylation Inhibitors versus 5-Aza-2′-Deoxycytidine. Mol. Cancer Ther. 2005, 4, 1515–1520.
154. Coronel J. Cetina L. Pacheco I. Trejo-Becerril C. Gonzalez-Fierro A. de La Cruz-Hernandez E. Perez-Cardenas E. Taja-Chayeb L. Arias-Bofill D. Candelaria M. A Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Chemotherapy Plus Epigenetic Therapy with Hydralazine Valproate for Advanced Cervical Cancer: Preliminary Results. Med Oncol 2010 Oct 8. [Epub ahead of print]
155. Candelaria M. Herrera A. Labardini J. Gonzalez-Fierro A. Trejo-Becerril C. Taja-Chayeb L. Perez-Cardenas E. de La Cruz-Hernandez E. Arias-Bofill D. Vidal S. Hydralazine and Magnesium Valproate as Epigenetic Treatment for Myelodysplastic Syndrome: Preliminary Results of a Phase-II Trial. Ann. Hematol. 2011, 90, 379–387.
156. Villar-Garea A. Fraga M. F. Espada J. Esteller M. Procaine Is a DNA-Demethylating Agent with Growth-Inhibitory Effects in Human Cancer Cells. Cancer Res. 2003, 63, 4984–4989.
157. Stresemann C. Brueckner B. Musch T. Stopper H. Lyko F. Functional Diversity of DNA Methyltransferase Inhibitors in Human Cancer Cell Lines. Cancer Res. 2006, 66, 2794–2800.
158. Fang M. Z. Wang Y. Ai N. Hou Z. Sun Y. Lu H. Welsh W. Yang C. S. Tea Polyphenol (–)-Epigallocatechin-3-Gallate Inhibits DNA Methyltransferase and Reactivates Methylation-Silenced Genes in Cancer Cell Lines. Cancer Res. 2003, 63, 7563–7570.
159. Siedlecki P. Garcia Boy R. Musch T. Brueckner B. Suhai S. Lyko F. Zielenkiewicz P. Discovery of Two Novel, Small-Molecule Inhibitors of DNA Methylation. J. Med. Chem. 2006, 49, 678–683.
160. Brueckner B. Garcia Boy R. Siedlecki P. Musch T. Kliem H. C. Zielenkiewicz P. Suhai S. Wiessler M. Lyko F. Epigenetic Reactivation of Tumor Suppressor Genes by a Novel Small-Molecule Inhibitor of Human DNA Methyltransferases. Cancer Res. 2005, 65, 6305–6311.
161. Lin R. K. Hsu C. H. Wang Y. C. Mithramycin A Inhibits DNA Methyltransferase and Metastasis Potential of Lung Cancer Cells. Anticancer Drugs 2007, 18, 1157–1164.
162. Datta J. Ghoshal K. Denny W. A. Gamage S. A. Brooke D. G. Phiasivongsa P. Redkar S. Jacob S. T. A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation. Cancer Res. 2009, 69, 4277–4285.
163. Kuck D. Caulfield T. Lyko F. Medina-Franco J. L. Nanaomycin A Selectively Inhibits DNMT3B and Reactivates Silenced Tumor Suppressor Genes in Human Cancer Cells. Mol. Cancer Ther. 2010, 9, 3015–3023.
164. Kuck D. Singh N. Lyko F. Medina-Franco J. L. Novel and Selective DNA Methyltransferase Inhibitors: Docking-Based Virtual Screening and Experimental Evaluation. Bioorg. Med. Chem. 2010, 18, 822–829.
165. Song J. Rechkoblit O. Bestor T. H. Patel D. J. Structure of DNMT1-DNA Complex Reveals a Role for Autoinhibition in Maintenance DNA Methylation. Science 2011, 331, 1036–1040.
166. http://www.ebi.ac.uk/chembldb/index.php
167. http://www.bindingdb.org
168. Yang X. Lay F. Han H. Jones P. A. Targeting DNA Methylation for Epigenetic Therapy. Trends Pharmacol. Sci. 2010, 31, 536–546.
169. Medina-Franco J. L. Caulfield T. Advances in the Computational Development of DNA Methyltransferase Inhibitors. Drug Discov. Today 2011, 16, 418–425.
170. Sharma S. Kelly T. K. Jones P. A. Epigenetics in cancer. Carcinogenesis 2010, 31, 27–36.
171. Lin J. C. Jeong S. Liang G. Takai D. Fatemi M. Tsai Y. C. Egger G. Gal-Yam E. N. Jones P. A. Role of Nucleosomal Occupancy in the Epigenetic Silencing of the MLH1 CpG Island. Cancer Cell 2007, 12, 432–444.
172. Margueron R. Reinberg D. The Polycomb Complex PRC2 and Its Mark in Life. Nature 2011, 469, 343–349.
173. Pradhan S. Chin H. G. Esteve P. O. Jacobsen S. E. SET7/9 Mediated Methylation of Non-Histone Proteins in Mammalian Cells. Epigenetics 2009, 4, 383–387.
174. Nicholson T. B. Chen T. LSD1 Demethylates Histone and Non-Histone Proteins. Epigenetics 2009, 4, 129–132.
175. Taby R. Issa J. P. Cancer Epigenetics. CA Cancer J. Clin. 2010, 60, 376–392.
176. Gollob J. A. Sciambi C. J. Peterson B. L. Richmond T. Thoreson M. Moran K. Dressman H. K. Jelinek J. Issa J. P. Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma. Clin. Cancer Res. 2006, 12, 4619–4627.
177. Soriano A. O. Yang H. Faderl S. Estrov Z. Giles F. Ravandi F. Cortes J. Wierda W. G. Ouzounian S. Quezada A. Safety and Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid, and All-Trans Retinoic Acid in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 2007, 110, 2302–2308.
178. Raza A. Mehdi M. Mumtaz M. Ali F. Lascher S. Galili N. Combination of 5-Azacytidine and Thalidomide for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer 2008, 113, 1596–1604.
179. Scott B. L. Ramakrishnan A. Storer B. Becker P. S. Petersdorf S. Estey E. H. Deeg H. J. Prolonged Responses in Patients with MDS and CMML Treated with Azacitidine and Etanercept. Br. J. Haematol. 2010, 148, 944–947.
180. Borthakur G. Huang X. Kantarjian H. Faderl S. Ravandi F. Ferrajoli A. Torma R. Morris G. Berry D. Issa J. P. Report of a Phase 1/2 Study of a Combination of Azacitidine and Cytarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes. Leuk. Lymphoma 2010, 51, 73–78.
181. Mack G. S. To Selectivity and Beyond. Nat. Biotechnol. 2010, 28, 1259–1266.
182. Kummar S. Chen H. X. Wright J. Holbeck S. Millin M. D. Tomaszewski J. Zweibel J. Collins J. Doroshow J. H. Utilizing Targeted Cancer Therapeutic Agents in Combination: Novel Approaches and Urgent Requirements. Nat. Rev. Drug Discov. 2010, 9, 843–856.